Key Takeaways:
- Armata Pharmaceuticals, Inc. ARMP reported a slight decrease in grant revenue for Q4 2025, attributed to its AP-SA02 program.
- The company operates in the biotechnology sector, focusing on bacteriophage therapeutics for antibiotic-resistant infections.
- Armata's financial health shows significant challenges, with negative profitability metrics and high volatility.
Armata Pharmaceuticals, Inc. (ARMP) reported grant revenue of $1.1 million for the fourth quarter ending December 31, 2025. This represents a slight decrease from the $1.2 million recorded in the same period the previous year. The revenue is attributed to MTEC’s contribution to the company’s AP-SA02 program, which focuses on developing treatments for Staphylococcus aureus bacteremia.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
With a market capitalization of $313.47 million, Armata operates within the healthcare sector, specifically in the biotechnology industry. The company is listed on the AMEX exchange and has a beta of 2.04, indicating a higher level of volatility compared to the market.
Financial Health Analysis
Armata Pharmaceuticals faces significant financial challenges, as evidenced by several key metrics:
- Revenue Growth: The company reported no revenue growth over the past three years, with a revenue growth rate of 0%.
- Profitability: Armata has a negative EPS of -1.62, and its net margin is significantly negative, with a median value of -7245.38.
- Balance Sheet: The company's debt-to-equity ratio is -1.86, indicating a high level of debt relative to equity. The current ratio and quick ratio are both at 0.12, suggesting liquidity concerns.
Valuation & Market Sentiment
Armata's valuation metrics reflect its distressed status:
- The P/E ratio is not applicable due to negative earnings.
- The P/S ratio ranges from 4.08 to 486.28, indicating significant variability in sales valuation.
- Analyst recommendations are neutral, with a recommendation score of 2.
- Technical indicators show a RSI (14) of 39.37, suggesting the stock is nearing oversold territory.
Risk Assessment
Armata Pharmaceuticals presents several risk factors:
- Financial Health: The company has a low Piotroski F-Score of 1, indicating weak financial strength.
- Volatility: With a beta of 2.04, the stock is highly volatile, which may deter risk-averse investors.
- Sector-Specific Risks: Operating in the biotechnology sector, Armata faces regulatory and clinical trial risks inherent to drug development.
In summary, while Armata Pharmaceuticals is actively developing innovative treatments for antibiotic-resistant infections, its financial health and market position present significant challenges. Investors should carefully consider these factors when evaluating the company's potential.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
